This company has been acquired
Paratek Pharmaceuticals Dividend
Dividend criteriumcontroles 0/6
Paratek Pharmaceuticals does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
n/a
Uitbetalingsratio
Gemiddelde opbrengst industrie | 2.2% |
Volgende betaaldatum dividend | n/a |
Ex-dividenddatum | n/a |
Dividend per aandeel | n/a |
Winst per aandeel | -US$1.09 |
Dividendrendementsvoorspelling | n/a |
Recente dividendupdates
Geen updates
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.
Dividendrendement versus markt
Paratek Pharmaceuticals Dividendrendement versus markt |
---|
Segment | Dividendrendement |
---|---|
Bedrijf (PRTK) | n/a |
Markt onderkant 25% (US) | 1.4% |
Markt Top 25% (US) | 4.4% |
Gemiddelde industrie (Pharmaceuticals) | 2.2% |
Analist prognose (PRTK) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as PRTK has not reported any payouts.